Coronavirus Update
Similar to Influenza A, coronavirus is an enveloped virus. While this would often serve to protect the virus from possible threats, SteraMist® features efficacy against Influenza A and similar, enveloped viral threats, including coronavirus.
Steramist® Efficacy
TOMI has EPA accepted studies on the current label to meet the standard to respond to emerging pathogens in the enveloped and non-enveloped categories, which include, SARS, MERS and CoViD-19, the current coronavirus outbreak*.
Trusted around the globe
With more than 50 international customers and partners ranging from countries in Asia, Europe, and the Mideast using hundreds of SteraMist units, many of which have been deployed to stop the spread of COVID-19.
Comparative Advantage
SteraMist has key competitive advantages over other disinfection methods listed in the chart below.
Routinely used to disinfect high traffic areas, SteraMist iHP technology has treated public transportation, ambulances, hotel rooms, offices, and universities to stop the spread of this virus.
With more than 50 international customers and partners ranging from countries in Asia, Europe, and the Mideast using hundreds of SteraMist units, many of which have been deployed to stop the spread of COVID-19.
An established five-year TOMI authorized distributor in South Korea, GD Sciences, has begun to address this problem by utilizing SteraMist technology in transit systems, focusing primarily on the metropolitan transit system of South Korea’s capital city, Seoul.
The annual ridership of the Seoul Metropolitan Subway is over 1.2 billion. This application has allowed SteraMist to become a critical line of defense as a preventative measure against the rapid spread of COVID-19.
